5414002025-01-012025-03-315414002025-03-315414002024-03-315414002024-04-012025-03-315414002025-01-012025-03-31in-capmkt:OtherExpenses1Member5414002024-04-012025-03-31in-capmkt:OtherExpenses1Member5414002025-01-012025-03-31ItemsThatWillNotBeReclassifiedToProfitAndLoss15414002024-04-012025-03-31ItemsThatWillNotBeReclassifiedToProfitAndLoss15414002025-01-012025-03-31ItemsThatWillBeReclassifiedToProfitAndLoss15414002024-04-012025-03-31ItemsThatWillBeReclassifiedToProfitAndLoss15414002025-01-012025-03-31AuditorDomain1iso4217:INRxbrli:pureiso4217:INRxbrli:shares541400ZIMLABNOTLISTEDINE518E01015ZIM Laboratories LimitedMain BoardEquity2024-04-012025-03-312025-05-202025-05-14INRLakhsQuarterlyFourth quarterSingle segmentPharmaceutical Industry2025-05-2015:00:002025-05-2019:30:00trueCash Flow IndirectDeclaration of unmodified opinion2025-01-012025-03-31UnauditedConsolidated108733000017098000110442800048600900032959000-36414000163246000290920005289000029556200010233440008108400008108400034033000-179400032239000048845000000048845000-39240004492100048847000-200044923000-2000487258000101.011.01001.011.010.00440.01880.0379Notes A to C <BR> <BR> 1 The above results were reviewed and recommended by the Audit Committee and approved by the Board of Directors at their respective meetings held on 20 May 2025 There are no qualifications in the audit report issued for the year ended 31 March 2025 <BR> <BR> 2 These financial results have been prepared in accordance with the recognition and measurement principles of applicable Indian Accounting Standard Ind AS notified under the Companies Indian Accounting Standards Rules 2015 as amended as prescribed under Section 133 of the Companies Act 2013 and other accounting principles generally accepted in India and is in compliance with the presentation and disclosure requirements of Regulation 33 of the Listing Regulations and guidelines issued by the Securities and Exchange Board of India SEBI <BR> <BR> 3 The figures for the quarter ended 31 March 2025 and 31 March 2024 represent the balance between audited figures in respect of the full financial years and those published till the third quarter of the respective financial years which were subjected to a limited review by the statutory auditor <BR> <BR> 4 The Company and its subsidiaries are principally engaged in a single business segment which is pharmaceuticals <BR> <BR> 5 Figures of previous period year have been regrouped rearranged wherever necessary The impact of the same is not material to the users of financial statement <BR> <BR> <BR> <BR> <BR> <BR> <BR> <BR> Place Nagpur Anwar Daud <BR> Date 20 May 2025 Managing Director2024-04-012025-03-31AuditedConsolidated379031000057841000384815100015500400001157820001266500060759800011388200020113400010669560003668057000180094000018009400046741000117030005844400001216500000000121650000-275000121375000121652000-2000121377000-20004872580001020351170002.52.5002.52.50.00440.01650.0258Other Expenses295562000Other Expenses106695600015834390004405440000169400057633000264105000005000000010327000108270000489180002407160000864700000010692030001946600054590000306700010971950000351179000231307400000472023400048725800020351170002522375000500025223800004030100000002069700042370700001105010000053420800071864500066846000628212000695058000152679000156638200061270000679000029204000016636460000021978540004720234000113882000-52071000-7990500000-1279000-674000-703500007124900000-60592000201134000000266780000-29990000511000135400000006473000-71970000220693000400787000000-10759000041154600000000000732000040797700000000000000000000750004590000853000-3992700000000000024624000017846700035816000012300200000-91045000-787690002233000-765360009600200019466000Measurements of defind employee benefit plans-3554000-3554000Measurements of defind employee benefit plans-7595000-7595000-1035000-2211000Exchange differenaces on translation of foreign operations-1405000-1405000Exchange differenaces on translation of foreign operations5109000510900000-3924000-275000AuditedtrueWalker Chandiok and Co LLPtrue2025-05-31